• Transient use of Tpo-RAs for refractory ITP in pregnancy seems relatively safe and effective for mother and fetus.

Management of immune thrombocytopenia (ITP) during pregnancy can be challenging because treatment choices are limited. Thrombopoietin receptor agonists (Tpo-RAs), which likely cross the placenta, are not recommended during pregnancy. To better assess the safety and efficacy of off-label use of Tpo-RAs during pregnancy, a multicenter observational and retrospective study was conducted. Results from 15 pregnant women with ITP (pregnancies, n = 17; neonates, n = 18) treated with either eltrombopag (n = 8) or romiplostim (n = 7) during pregnancy, including 2 patients with secondary ITP, were analyzed. Median time of Tpo-RA exposure during pregnancy was 4.4 weeks (range, 1-39 weeks); the indication for starting Tpo-RAs was preparation for delivery in 10 (58%) of 17 pregnancies, whereas 4 had chronic refractory symptomatic ITP and 3 were receiving eltrombopag when pregnancy started. Regarding safety, neither thromboembolic events among mothers nor Tpo-RA–related fetal or neonatal complications were observed, except for 1 case of neonatal thrombocytosis. Response to Tpo-RAs was achieved in 77% of cases, mostly in combination with concomitant ITP therapy (70% of responders). On the basis of these preliminary findings, temporary off-label use of Tpo-RAs for severe and/or refractory ITP during pregnancy seems safe for both mother and neonate and is likely to be helpful, especially before delivery.

1.
McCrae
KR
.
Thrombocytopenia in pregnancy
.
Hematology Am Soc Hematol Educ Program
.
2010
;
2010
:
397
-
402
.
2.
Gernsheimer
T
,
James
AH
,
Stasi
R
.
How I treat thrombocytopenia in pregnancy
.
Blood
.
2013
;
121
(
1
):
38
-
47
.
3.
Loustau
V
,
Debouverie
O
,
Canoui-Poitrine
F
, et al
.
Effect of pregnancy on the course of immune thrombocytopenia: a retrospective study of 118 pregnancies in 82 women
.
Br J Haematol
.
2014
;
166
(
6
):
929
-
935
.
4.
Rodeghiero
F
,
Stasi
R
,
Gernsheimer
T
, et al
.
Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group
.
Blood
.
2009
;
113
(
11
):
2386
-
2393
.
5.
Provan
D
,
Arnold
DM
,
Bussel
JB
, et al
.
Updated international consensus report on the investigation and management of primary immune thrombocytopenia
.
Blood Adv
.
2019
;
3
(
22
):
3780
-
3817
.
6.
Sun
D
,
Shehata
N
,
Ye
XY
, et al
.
Corticosteroids compared with intravenous immunoglobulin for the treatment of immune thrombocytopenia in pregnancy
.
Blood
.
2016
;
128
(
10
):
1329
-
1335
.
7.
Chakravarty
EF
,
Murray
ER
,
Kelman
A
,
Farmer
P
.
Pregnancy outcomes after maternal exposure to rituximab
.
Blood
.
2011
;
117
(
5
):
1499
-
1506
.
8.
Bleau
N
,
Czuzoj-Shulman
N
,
Spence
AR
,
Abenhaim
HA
.
Safety of splenectomy during pregnancy
.
J Matern Fetal Neonatal Med
.
2017
;
30
(
14
):
1671
-
1675
.
9.
Mahey
R
,
Kaur
SD
,
Chumber
S
,
Kriplani
A
,
Bhatla
N
.
Splenectomy during pregnancy: treatment of refractory immune thrombocytopenic purpura
.
BMJ Case Rep
.
2013
;
2013
:
bcr2013201778
.
10.
Kong
Z
,
Qin
P
,
Xiao
S
, et al
.
A novel recombinant human thrombopoietin therapy for the management of immune thrombocytopenia in pregnancy
.
Blood
.
2017
;
130
(
9
):
1097
-
1103
.
11.
Liu
Y
,
Wang
R
,
Han
P
, et al
.
Effect of recombinant human thrombopoietin on immune thrombocytopenia in pregnancy in a murine model
.
Int Immunopharmacol
.
2019
;
67
:
287
-
293
.
12.
Ghanima
W
,
Cooper
N
,
Rodeghiero
F
,
Godeau
B
,
Bussel
JB
.
Thrombopoietin receptor agonists: ten years later
.
Haematologica
.
2019
;
104
(
6
):
1112
-
1123
.
13.
Alkaabi
JK
,
Alkindi
S
,
Riyami
NA
,
Zia
F
,
Balla
LM
,
Balla
SM
.
Successful treatment of severe thrombocytopenia with romiplostim in a pregnant patient with systemic lupus erythematosus
.
Lupus
.
2012
;
21
(
14
):
1571
-
1574
.
14.
Purushothaman
J
,
Puthumana
KJ
,
Kumar
A
,
Innah
SJ
,
Gilvaz
S
.
A case of refractory immune thrombocytopenia in pregnancy managed with elthrombopag
.
Asian J Transfus Sci
.
2016
;
10
(
2
):
155
-
158
.
15.
Decroocq
J
,
Marcellin
L
,
Le Ray
C
,
Willems
L
.
Rescue therapy with romiplostim for refractory primary immune thrombocytopenia during pregnancy
.
Obstet Gynecol
.
2014
;
124
(
2 Pt 2 suppl 1
):
481
-
483
.
16.
Patil
AS
,
Dotters-Katz
SK
,
Metjian
AD
,
James
AH
,
Swamy
GK
.
Use of a thrombopoietin mimetic for chronic immune thrombocytopenic purpura in pregnancy
.
Obstet Gynecol
.
2013
;
122
(
2 Pt 2
):
483
-
485
.
17.
Suzuki
N
,
Hiraga
J
,
Hariyama
Y
, et al
.
A low birth weight infant with no malformations delivered by a primary immune thrombocytopenia patient treated with eltrombopag
.
Int J Hematol
.
2018
;
108
(
1
):
109
-
111
.
18.
Rodrigues-Nunes
RM
,
Rubio Lacambra
L
,
Palomo Bravo
A
,
Langenhorst Baniandres
L
.
Use of romiplostim during pregnancy as a rescue therapy in primary immune thrombocytopenia: literature review and case description
.
Platelets
.
2020
;
31
(
3
):
403
-
406
.
19.
Ferreira
IJMCF
,
Sousa
F
,
Vasco
EM
, et al
.
Severe immune thrombocytopenia in pregnancy treated with eltrombopag - a case report
.
J Gynecol Obstet Hum Reprod
.
2018
;
47
(
8
):
405
-
408
.
20.
Chon
AH
,
Chan
R
,
Lee
RH
,
Kwong
K
,
Wertheimer
FB
,
Weitz
IC
.
Multidrug therapy for refractory immune thrombocytopenia in pregnancy
.
Obstet Gynecol
.
2020
;
135
(
3
):
723
-
727
.
21.
Favier
R
,
De Carne
C
,
Elefant
E
,
Lapusneanu
R
,
Gkalea
V
,
Rigouzzo
A
.
Eltrombopag to treat thrombocytopenia during last month of pregnancy in a woman with MYH9-related disease: a case report
.
A A Pract
.
2018
;
10
(
1
):
10
-
12
.
22.
Guitton
Z
,
Terriou
L
,
Lega
JC
, et al
.
Risk of thrombosis with anti-phospholipid syndrome in systemic lupus erythematosus treated with thrombopoietin-receptor agonists
.
Rheumatology (Oxford)
.
2018
;
57
(
8
):
1432
-
1438
.
23.
Webert
KE
,
Mittal
R
,
Sigouin
C
,
Heddle
NM
,
Kelton
JG
.
A retrospective 11-year analysis of obstetric patients with idiopathic thrombocytopenic purpura
.
Blood
.
2003
;
102
(
13
):
4306
-
4311
.
You do not currently have access to this content.

Sign in via your Institution

Sign In